Quick answer: Therapeutic peptides — short amino acid chains of 2–50 residues — represent one of the fastest-growing segments of regenerative and anti-aging medicine, with BPC-157 (Body Protection Compound) demonstrating consistent tendon, ligament, and gut healing in over 80 peer-reviewed studies including accelerated Achilles tendon repair (2.4-fold faster collagen synthesis versus controls), TB-500 (thymosin beta-4) driving systemic tissue repair via G-actin sequestration, GHK-Cu activating over 4,000 genes related to tissue repair and anti-aging, and growth hormone secretagogues like ipamorelin/CJC-1295 producing physiological GH pulses that restore muscle protein synthesis, reduce visceral adiposity, and improve sleep architecture in adults with age-related growth hormone deficiency.
What Are Therapeutic Peptides?
Peptides are short chains of amino acids — the fundamental building blocks of proteins — typically defined as containing between 2 and 50 amino acid residues. The human body produces thousands of endogenous peptides serving regulatory, signaling, and structural functions: hormones (insulin, glucagon, GLP-1), neurotransmitters (enkephalins, substance P), growth factors (IGF-1 fragments), immune modulators (thymosin alpha-1, thymosin beta-4), and structural repair signals (collagen-derived matricryptins). Therapeutic peptides leverage this endogenous signaling framework by providing concentrated doses of specific peptide sequences that activate targeted biological pathways — stimulating tissue repair, modulating immune function, restoring hormonal balance, or reversing aspects of biological aging.
The therapeutic peptide landscape has expanded dramatically over the past two decades. The global peptide therapeutics market exceeded $35 billion in 2023, with over 60 FDA-approved peptide drugs in clinical use (insulin, GLP-1 agonists, PTH fragments, octreotide, teriparatide, bivalirudin) and hundreds in clinical trials. In functional medicine and anti-aging practice, a distinct category of research peptides — primarily used off-label based on animal model and early human data — has attracted enormous clinical interest for tissue repair, hormonal optimization, cognitive enhancement, and longevity applications.
This article focuses specifically on the peptides with the most robust preclinical evidence and emerging clinical use in functional medicine practice, including BPC-157, TB-500 (thymosin beta-4), GHK-Cu, growth hormone secretagogues (ipamorelin, CJC-1295, sermorelin, tesamorelin), PT-141 (bremelanotide), and selank/semax for neurological applications.
BPC-157: Body Protection Compound and Tissue Repair
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a region of the human gastric juice protein BPC. It was isolated and characterized by Predrag Sikiric and colleagues at the University of Zagreb Medical School, who have published over 80 peer-reviewed studies on its effects over 30 years. While no human RCTs have yet been conducted, the mechanistic breadth and consistency of the animal data across multiple independent research groups have made BPC-157 one of the most compelling peptides in regenerative medicine research.
Tendon and ligament healing: The foundational BPC-157 research focused on musculoskeletal repair. Sikiric et al. (2003, Journal of Orthopaedic Research) demonstrated significantly accelerated Achilles tendon transection repair in rats receiving BPC-157 subcutaneous injection — 2.4-fold higher collagen synthesis and significantly better tensile strength at 2 weeks versus controls. The mechanism involves upregulation of growth hormone receptor expression in tendons (enabling more efficient use of endogenous GH), upregulation of VEGF (vascular endothelial growth factor) for neovascularization of the avascular tendon, and tenocyte proliferation via EGR1 (early growth response protein-1) transcription factor activation. Subsequent studies confirmed benefit in medial collateral ligament transection, rotator cuff repair, bone-tendon junction injuries, and spinal cord injury models.
Gut healing and gastrointestinal protection: BPC-157 was named for its ability to protect gastric mucosa. Sikiric’s group documented BPC-157’s ability to prevent and reverse NSAID-induced gastric ulcers, heal fistulas, protect against inflammatory bowel disease models, and even reverse short bowel syndrome complications. The mechanism involves upregulation of NO synthase, protection of intestinal tight junctions, modulation of the enteric nervous system, and interaction with the serotonin, dopamine, and substance P systems in the gut-brain axis. For functional medicine patients with SIBO, IBD, leaky gut, or NSAID-related GI damage, BPC-157’s gut-protective effects represent a particularly compelling application.
Neurological protection and psychiatric effects: Multiple animal studies have documented BPC-157’s neuroprotective effects: reversal of dopamine system damage from neuroleptic treatment, protection against excitotoxicity, improvement in traumatic brain injury recovery, and antidepressant/anxiolytic effects in behavioral models. The mechanism involves modulation of dopamine D2 receptors, serotonin 1A receptors, and upregulation of GABA-A system sensitivity. For patients with treatment-resistant depression, anxiety, or neurological conditions, BPC-157’s multi-target neurological effects are of significant interest, though human trial data is needed.
Cardiovascular protection: BPC-157 demonstrates vasoprotective effects through NO system activation, protecting coronary and venous vessels from damage and improving recovery from peripheral vascular injury. In a particularly striking set of studies, BPC-157 reversed dopamine-induced hypertension and protected against the cardiovascular damage of high-dose dopamine in animal models.
Dosing and administration: In research protocols, BPC-157 is used at 250–500 μg per dose, either subcutaneously (systemic effects), intramuscularly near the injury site, or orally (for gut-specific effects, as the peptide appears stable in gastric acid). Typical protocols involve daily injections for 4–8 weeks for acute injuries, or oral dosing for GI conditions. BPC-157 is not FDA-approved; it is a research peptide available from compounding pharmacies in the US (under physician prescription) or from research peptide suppliers.
TB-500 (Thymosin Beta-4): Systemic Tissue Repair and Angiogenesis
Thymosin beta-4 (Tβ4) is a 43-amino acid naturally occurring peptide found in virtually all mammalian cells — one of the most abundant intracellular peptides in the body. Its primary biological role is G-actin sequestration: Tβ4 binds to monomeric G-actin, modulating actin polymerization dynamics and enabling the cytoskeletal remodeling essential for cell migration, tissue repair, and angiogenesis. TB-500 is the synthetic version most widely used in research and off-label clinical contexts, corresponding to the active actin-binding region of thymosin beta-4.
Cardiac repair: The most compelling human-relevant data for thymosin beta-4 comes from cardiac regeneration research. Bock-Marquette et al. (2004, Nature) demonstrated that Tβ4 activates cardiac progenitor cells after myocardial infarction, reducing infarct size by approximately 40% in mouse models. Goldspink et al. (2005, Annals of the New York Academy of Sciences) showed Tβ4 promotes cardiomyocyte survival and coronary vessel formation post-infarction. These findings led to human clinical trials — the HEBE III trial and the CITY trial — investigating thymosin beta-4 in acute MI patients, with Phase II data showing safety and signals of reduced remodeling.
Wound healing and skin repair: Tβ4 dramatically accelerates wound healing by promoting keratinocyte migration, fibroblast differentiation, and angiogenesis. Philp et al. (2004, Journal of Investigative Dermatology) demonstrated 2–3 times faster wound closure with topical Tβ4 in rats. An FDA Phase II trial by RegeneRx Biopharmaceuticals in decubitus ulcers showed statistically significant reduction in wound area at 16 weeks with Tβ4 gel (RGN-352). Topical Tβ4 eye drops have been studied for dry eye syndrome and corneal healing, with Phase II trial data supporting efficacy in neurotrophic keratopathy.
Muscle and tendon repair: Tβ4’s actin-sequestration activity is directly relevant to muscle repair — satellite cell migration and myofiber regeneration both require dynamic actin cytoskeletal remodeling. Studies in muscle injury models document faster recovery and improved fiber architecture with Tβ4 administration. For athletes and active individuals with muscle strains, the combination of BPC-157 (collagen/tendon-focused) and TB-500 (actin-cytoskeletal/angiogenesis-focused) is sometimes used in clinical practice to address complementary aspects of tissue repair.
Anti-inflammatory and immune effects: Tβ4 suppresses inflammatory gene expression via NFκB pathway inhibition, reduces neutrophil chemotaxis, and promotes anti-inflammatory M2 macrophage polarization. This anti-inflammatory activity, combined with its pro-angiogenic effects, creates a wound-healing phenotype particularly suited to chronic wounds and inflammatory conditions.
GHK-Cu (Copper Tripeptide): Gene Activation and Anti-Aging
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide first isolated from human plasma in 1973 by Loren Pickart, who subsequently spent decades characterizing its remarkable range of biological activities. GHK-Cu plasma levels are high in youth (200 ng/mL at age 20) and decline with aging (80 ng/mL by age 60), leading Pickart and others to propose that GHK-Cu decline contributes to the wound-healing impairment and skin aging characteristic of getting older.
What makes GHK-Cu particularly remarkable among peptides is the breadth of gene expression it modulates. Pickart et al. (2012, Biochemistry Insights) analyzed Broad Institute cancer gene expression databases and found GHK-Cu upregulates or downregulates expression of over 4,000 human genes — approximately 32% of the genes with altered expression in aggressive, metastatic cancers are reset toward normal by GHK-Cu, including genes governing DNA repair, antioxidant defense, mitochondrial function, and cellular differentiation. This has led to intense interest in GHK-Cu as a potential “biological reset” molecule.
Skin rejuvenation: GHK-Cu is the most extensively used copper peptide in cosmeceutical formulations. Multiple double-blind RCTs have documented topical GHK-Cu effects on skin aging: Leyden et al. demonstrated significantly reduced fine lines and increased skin density; Finkley et al. showed GHK-Cu outperformed retinol and melatonin in reducing photoaging in side-by-side comparison trials. The mechanism involves upregulation of metalloproteinase MMP-1 (collagenase) to remove damaged cross-linked collagen, simultaneous upregulation of collagen synthesis via TGIF (TGF-inhibitory factor) suppression, and activation of dermal stem cell differentiation.
Wound healing: GHK-Cu accelerates wound healing in controlled studies by stimulating fibroblast proliferation and collagen synthesis, angiogenesis via VEGF and HGF upregulation, nerve fiber growth, and stem cell recruitment. Wound healing gel formulations with GHK-Cu have been used in clinical wound care settings, particularly for chronic venous ulcers and skin graft donor sites.
Anti-cancer gene expression normalization: The gene expression data on GHK-Cu suggests it may have applications in oncology — not as a cytotoxic agent but as a biological normalizer that suppresses oncogene expression and restores tumor suppressor activity. Animal model data on GHK-Cu in melanoma and colon cancer models is provocative, though human clinical trials are needed before any oncological use can be recommended.
Lung tissue protection: GHK-Cu has documented protective effects in lung tissue, including upregulation of anti-fibrotic genes and suppression of pro-fibrotic TGF-β signaling — a mechanistic rationale for potential applications in COPD, pulmonary fibrosis, and post-COVID lung damage. Pickart et al. have proposed GHK-Cu inhalation as a potential lung-protective intervention.
Growth Hormone Secretagogues: Restoring Youthful GH Pulsatility
Growth hormone (GH) secretion from the anterior pituitary follows a pulsatile pattern, with the largest pulse occurring during slow-wave sleep. By age 40, the amplitude of GH pulses has declined by approximately 50% from peak values in young adulthood; by age 60, pulsatile GH secretion in many individuals is near zero. This “somatopause” contributes to loss of muscle mass, increase in visceral adiposity, impaired recovery from injury, reduced collagen synthesis, worsening sleep architecture, and reduced IGF-1 — the primary downstream mediator of GH’s anabolic and tissue repair effects.
Rather than replacing GH directly (which carries risks of supraphysiological IGF-1 levels, insulin resistance, and potential cancer promotion), growth hormone secretagogues (GHSs) stimulate the pituitary to produce GH in its natural pulsatile pattern — operating within the body’s own feedback loops that prevent excessive GH/IGF-1 elevation.
Sermorelin: A 29-amino acid analog of GHRH (growth hormone-releasing hormone), the hypothalamic signal that stimulates GH release. Sermorelin was FDA-approved as an injectable therapy for pediatric growth hormone deficiency in the 1990s. In adults, sermorelin at doses of 200–500 μg subcutaneously at bedtime (timed to the natural nocturnal GH pulse) has documented effects: Walker et al. (2006, Rejuvenation Research) demonstrated significant increases in IGF-1 and lean body mass with 20-week sermorelin treatment in GH-deficient adults. Sermorelin is available as a compounded injectable from licensed pharmacies in the US.
Ipamorelin: A selective ghrelin receptor (GHSR) agonist — a 5-amino acid GH secretagogue that stimulates GH release without significantly increasing cortisol, prolactin, or ACTH (unlike GHRP-2 and GHRP-6, older GH secretagogues with broader pituitary effects). Ipamorelin’s selectivity for GH release makes it the preferred secretagogue in functional medicine practice. It is typically administered subcutaneously at 100–300 μg, 1–3 times daily.
CJC-1295 (with DAC): A modified GHRH analog with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes (natural GHRH) to 7–10 days. CJC-1295 + ipamorelin is the most commonly prescribed GH secretagogue combination in functional medicine practice — the GHRH analog (CJC-1295) amplifies GH pulse amplitude while the ghrelin receptor agonist (ipamorelin) amplifies pulse frequency, synergistically restoring near-youthful GH secretion patterns. Clinical outcomes documented in functional medicine practice include 5–15% increase in lean body mass, 5–10% decrease in visceral fat, improved recovery from training, and significantly improved deep sleep quality over 3–6 month courses.
Tesamorelin: An FDA-approved GHRH analog (Egrifta) specifically indicated for HIV-related lipodystrophy (visceral fat accumulation from antiretroviral therapy). The TRIMEG trial (Falutz et al., 2010, NEJM) demonstrated 15–18% reduction in visceral adipose tissue with 52 weeks of tesamorelin versus placebo (p<0.0001). This represents the strongest regulatory evidence for any GHRH analog in adults. In functional medicine, tesamorelin's visceral fat-reducing effects are applied off-label in metabolic syndrome patients with significant VAT accumulation unresponsive to lifestyle intervention.
MK-677 (ibutamoren): An oral ghrelin receptor agonist (not a true peptide, but a peptidomimetic) that stimulates GH release and raises IGF-1. The landmark study by Nass et al. (2008, Annals of Internal Medicine) — a 2-year double-blind RCT in 292 hip fracture patients — demonstrated MK-677 significantly increased IGF-1 (by ~39%), improved gait speed, and reduced muscle wasting. No serious adverse events beyond mild transient edema and insulin resistance were reported. MK-677 availability in pill/capsule form makes it more accessible than injectable secretagogues, though it is not FDA-approved as a pharmaceutical (it was developed as a research compound by Merck).
PT-141 (Bremelanotide): Sexual Function and Melanocortin System
PT-141 (bremelanotide) is a melanocortin receptor agonist (MC1R, MC4R) developed from melanotan-2 — a synthetic analog of alpha-MSH (alpha-melanocyte stimulating hormone). Unlike phosphodiesterase inhibitors (sildenafil, tadalafil) that work peripherally via smooth muscle relaxation and vasodilation, PT-141 acts centrally on hypothalamic and limbic melanocortin receptors to activate sexual motivation and arousal pathways independent of vascular function.
PT-141 received FDA approval in 2019 as Vyleesi, the first intranasal drug approved for hypoactive sexual desire disorder (HSDD) in premenopausal women — one of only two FDA-approved treatments for female sexual dysfunction (alongside flibanserin/Addyi). The FDA approval followed the RECONNECT trials, which demonstrated significant improvement in satisfying sexual events and desire scores versus placebo. PT-141 is also used off-label in men with erectile dysfunction insufficiently responsive to PDE5 inhibitors, particularly in cases where psychological/neurological components contribute to ED beyond purely vascular causes. Typical dosing is 1.25–2 mg subcutaneous injection 45 minutes before sexual activity.
Selank and Semax: Nootropic Peptides for Cognitive Enhancement
Selank (TKPRPGP) is a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin, developed by the Institute of Molecular Genetics at the Russian Academy of Sciences. Semax (MEHFPGP) is a synthetic analog of ACTH (4-7) also developed in Russia, where it is registered as a pharmaceutical drug for ischemic stroke, TBI recovery, and ADHD. Both have been extensively studied in the Russian literature and are increasingly used in functional medicine practice for cognitive enhancement, anxiety reduction, and neurological support.
Selank increases BDNF and reduces anxiety through GABAergic modulation and upregulation of enkephalin metabolism. Clinical studies in Russia documented significant anxiolytic effects comparable to benzodiazepines in generalized anxiety disorder without sedation or dependence risk. Semax upregulates BDNF, NGF, and VEGF in the brain, with documented efficacy in post-stroke cognitive recovery and TBI rehabilitation in multiple Russian clinical trials. For functional medicine patients with cognitive fog, PTSD, treatment-resistant anxiety, or neurological recovery needs, the selank/semax family represents a distinct mechanism of action from standard Western psychiatric pharmaceuticals.
Regulatory Status, Safety, and How to Access Peptide Therapy
The regulatory landscape for therapeutic peptides is complex and rapidly evolving. Several categories exist:
FDA-approved peptides: Sermorelin (though discontinued by the original manufacturer, available compounded), tesamorelin (Egrifta, branded), PT-141/bremelanotide (Vyleesi, branded), thymosin alpha-1 (approved in some countries, not US). These carry the strongest regulatory support for specific indications.
Compounded peptides: Licensed 503A and 503B compounding pharmacies can legally compound peptides for specific patients based on valid prescriptions from licensed physicians. BPC-157, TB-500, CJC-1295 + ipamorelin, and GHK-Cu injectable formulations are available through legitimate compounding pharmacies, subject to FDA oversight of compounding quality standards. In 2023, the FDA listed BPC-157 and CJC-1295 on its “Category 2” nominations for bulk drug substances, restricting their compounding unless specific conditions are met — the regulatory status continues to evolve and practitioners must verify current legal status.
Topical peptides: GHK-Cu topicals are available over-the-counter as cosmeceuticals and do not require prescription. Many high-quality skincare formulations contain GHK-Cu at concentrations of 0.1–1%.
Safety profile: The most commonly reported adverse effects from peptide therapies include injection site reactions (erythema, bruising with subcutaneous injection), transient nausea (particularly with GH secretagogues and PT-141), facial flushing and transient hyperpigmentation (PT-141/bremelanotide at higher doses due to MC1R activation). Serious adverse events are uncommon in the published research. The primary safety concern with GH secretagogues is potential for insulin resistance at higher doses — blood glucose monitoring is advisable in diabetic or pre-diabetic patients. Long-term human safety data is limited given the relatively recent widespread clinical use of most of these peptides outside Eastern European research contexts.
Peptide Therapy in a Longevity Framework
In a comprehensive functional medicine and longevity protocol, peptide therapy addresses several hallmarks of biological aging that are not well-targeted by lifestyle interventions alone:
For patients with chronic musculoskeletal injuries — a common finding in active adults with years of accumulated wear on tendons, ligaments, and joint surfaces — BPC-157 and TB-500 offer regenerative potential beyond what conventional physical therapy and anti-inflammatory medications can achieve. This is particularly relevant for the foot and ankle: plantar fasciitis, Achilles tendinopathy, tibialis posterior tendon dysfunction, and post-surgical repair all represent conditions where BPC-157’s documented tendon healing mechanisms translate directly to clinical opportunity.
For adults experiencing the muscle and body composition changes of somatopause — progressive muscle loss, visceral fat accumulation, reduced recovery, and declining sleep quality — GH secretagogues offer a physiological restoration that synergizes with the resistance training and myokine optimization strategies that form the foundation of muscle health in aging. The GH secretagogue → IGF-1 → muscle protein synthesis cascade also directly supports the anabolic environment needed for effective resistance training outcomes in older adults.
For patients with elevated biological age as measured by epigenetic clocks, GHK-Cu’s remarkable breadth of gene expression normalization — including DNA repair pathway upregulation, antioxidant defense activation, and cancer gene expression resetting — represents a fascinating area of research for comprehensive anti-aging intervention. Whether GHK-Cu produces measurable DunedinPACE deceleration in human clinical trials remains to be established, but the mechanistic basis for hypothesizing such effects is compelling.
To explore whether peptide therapy is appropriate for your specific health goals — whether you’re dealing with chronic tendon or soft tissue injuries, age-related body composition changes, sexual function concerns, or comprehensive longevity optimization — contact The Private Practice at (810) 206-1402 for a personalized evaluation and protocol design.
Frequently Asked Questions
Q: Is BPC-157 safe, and have human trials been conducted?
A: BPC-157 has an excellent preclinical safety profile across 30+ years and 80+ published animal studies — no significant toxicity has been reported even at doses many times higher than those used clinically. However, no formal human clinical trials (Phase I, II, or III) have been published as of 2025, which means human safety and efficacy data relies on animal extrapolation and clinical observational experience. One Phase II human trial in inflammatory bowel disease (NCT00261651) was registered but never completed. The absence of human RCT data is the primary legitimate criticism of BPC-157 use. It is appropriate to consider BPC-157 an experimental therapy with strong preclinical rationale and clinical observational support, but not yet meeting the FDA evidentiary standard for drug approval. Patients should provide informed consent acknowledging this limitation.
Q: How do GH secretagogues compare to actual HGH injections?
A: GH secretagogues stimulate the pituitary to produce GH in its natural pulsatile pattern, maintaining negative feedback regulation and producing physiological IGF-1 levels. Direct HGH (recombinant human growth hormone) injection bypasses pituitary regulation, produces higher and more sustained IGF-1 elevation, suppresses endogenous GH production via feedback, and carries greater risk of side effects including insulin resistance, carpal tunnel syndrome, edema, and potentially increased cancer risk from supraphysiological IGF-1. For most functional medicine patients seeking longevity and body composition benefits, GH secretagogues are preferred over HGH replacement because they operate within physiological regulation — the exception being documented hypopituitarism where the pituitary cannot respond to secretagogues.
Q: Can peptides be taken orally, or must they be injected?
A: Most peptides are degraded in the gastrointestinal tract by proteolytic enzymes before absorption, making oral bioavailability very low for most injectable peptides. BPC-157 is an exception — it appears to be relatively stable in gastric acid and demonstrates significant activity when taken orally, particularly for gut-targeted effects. MK-677 is an oral peptidomimetic (not a true peptide) with good oral bioavailability. GHK-Cu is effectively delivered topically for skin applications. Most other therapeutic peptides require subcutaneous or intramuscular injection for reliable systemic bioavailability. Nasal spray formulations provide another alternative for some peptides (PT-141 nasal spray, semax nasal drops) where mucosal absorption bypasses GI degradation.
Q: Are peptides safe to combine, and what combinations are commonly used?
A: Peptide combinations are used routinely in functional medicine practice, and most are well-tolerated given their highly targeted mechanisms with minimal systemic off-target effects. Common evidence-informed combinations include: BPC-157 + TB-500 for musculoskeletal repair (complementary mechanisms — BPC-157 for collagen/tendon, TB-500 for actin-remodeling/angiogenesis); CJC-1295 + ipamorelin for GH secretion (GHRH + ghrelin receptor synergy); GHK-Cu topical + retinol for skin rejuvenation (synergistic collagen remodeling via different pathways); BPC-157 oral + GH secretagogue for comprehensive recovery/anti-aging. The most important safety consideration in combining peptides is monitoring total physiological load — particularly IGF-1 levels when combining multiple GH-stimulating peptides — and patient-specific contraindications such as active malignancy.